Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 dec 2015 - 16:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma presents an update on its Phase II trial with ATIR101™ at the American Society of Hematology 2015 Annual Meeting
Bericht
- Statistically significant increase in Overall Survival and reduction in Transplant Related Mortality observed in comparison to a historical control group
- Zero patients developed grade III-IV acute Graft-versus-Host-Disease upon infusion of ATIR101™
- Analysis of full read out of primary endpoint data anticipated to be reported in April 2016
Amsterdam, The Netherlands, December 7, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today presents data from its ongoing Phase II clinical trial in leukaemia patients at the American Society of Hematology (ASH) 57th Annual Meeting in Orlando, Florida.
The Company presents an update on its fully enrolled ongoing open label Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ added as a donor lymphocyte infusion to a haploidentical T-cell depleted stem cell transplantation.
Data presented in Session 732 (Clinical Allogeneic Transplantation) have a cut off date of November 23, 2015. As per that date a statistically significant reduction in Transplant Related Mortality (TRM) and a statistically significant increase in Overall Survival (OS) is observed in comparison to a historical control group based on Kaplan-Meier estimates (p=0.002 and p=0.0006 respectively).
Datum laatste update: 28 juli 2024